April 24, 2013 – Dr. McAllister presented Cytograft's clinical progress at the American Heart Association's Emerging Science Series "Innovations in Vascular Bioengineering"
      • Webinar recording available HERE.
April 17, 2013 - Dr. L’Heureux presented a webinar for young professionals on "Developing an Industry Career in Biomedical Engineering". More information available via BMES.
April 10, 2013 – Society for Biomaterials 2013 Annual Meeting- Adam Young presented on work creating dermal fillers using Cytograft's TESA technology.
December 8, 2012 - Dr. L’Heureux was invited to Tianjin to speak at the International Symposium on Small Diameter Vascular Grafts.
April 23, 2012 – Dr. L’Heureux reports a new process with cell synthesized threads at the annual FASEB meeting.
      • Press release can be found HERE.
      • Scientific American story HERE.
      • MIT Technology Review HERE.

AV Access for Hemodialysis: Cytograft has clinical trials ongoing in both Europe and South America. The autologous version of the graft has a commercialization permit and can be sold in Germany. Clinical results from Cytograft’s lead product, the Lifeline™ graft for hemodialysis access have been reported in both the New England Journal of Medicine and the Lancet.

Lower Limb Bypass for Critical Limb Ischemia: The Lifeline™ graft will soon be available to a select cohort of patients suffering from critical limb ischemia that have been targeted for amputation. The Lifeline™ graft, coupled with cell injections into the lower limb will be available for 'no option' patients in an attempt to delay or even avoid amputation. Patients with severe critical limb ischemia that are interested in enrolling in this study can email here for more information: CLI_clinicaltrials@cytograft.com.

Updates will be posted on this website and will also be available on www.clinicaltrials.gov.